![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Promega Gets CE Mark for Solid Tumor Diagnostic
Promega Gets CE Mark for Solid Tumor Diagnostic
![CE mark](https://www.fdanews.com/ext/resources/images/ce-mark.gif?t=1627682539&width=430)
Wisconsin-based Promega has earned a CE mark for its OncoMate MSI Dx analysis system for detecting microsatellite instability (MSI) in solid tumors.
MSI biomarkers can be used to predict a patient’s response to immune-oncology therapies for certain cancers.
“Screening cancer patients with these reliable markers” can help guide care and treatment decisions, the company said.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct